Insmed Q3 2023 Earnings Report $70.44 +1.03 (+1.48%) (As of 12/20/2024 05:31 PM ET) Earnings HistoryForecast Insmed EPS ResultsActual EPS-$1.10Consensus EPS -$1.06Beat/MissMissed by -$0.04One Year Ago EPSN/AInsmed Revenue ResultsActual Revenue$79.07 millionExpected Revenue$78.86 millionBeat/MissBeat by +$210.00 thousandYoY Revenue GrowthN/AInsmed Announcement DetailsQuarterQ3 2023Date10/26/2023TimeN/AConference Call ResourcesPress ReleaseINSM Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Insmed Earnings HeadlinesInsmed Incorporated (NASDAQ:INSM) Receives $83.67 Consensus Price Target from AnalystsDecember 16, 2024 | americanbankingnews.comShould You Invest in Insmed Incorporated (INSM)?December 9, 2024 | insidermonkey.comMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.December 21, 2024 | Brownstone Research (Ad)Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)December 6, 2024 | prnewswire.comInsmed To Present at December 2024 Investor ConferencesDecember 2, 2024 | prnewswire.comOptimistic Revenue Forecast for Insmed Following Brensocatib’s Launch and Strategic DevelopmentsNovember 23, 2024 | markets.businessinsider.comSee More Insmed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Insmed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Insmed and other key companies, straight to your email. Email Address About InsmedInsmed (NASDAQ:INSM) is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.View Insmed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
